Series B · BiotechSidewinder Therapeutics: Series BDevelops next-generation bispecific ADCs for cancer treatmentPublished Oct 4, 2026By RoundOS Funding deskFunding historyApr 8, 2026Series B · This round$137MSourcesbusinesswire.com↗
Isomorphic LabsBuilds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas$5BSeries C · Nov 17, 2026
Science CorporationDevelops brain-computer interface retinal implants to restore vision in patients with retinal diseases$400MSeries D · Nov 17, 2026
ZyaZya develops enzyme ingredients for food manufacturers, designed to transform nutrients after consumption.£11.5MSeries A · Nov 16, 2026
INFevoDevelops virtual-cell AI models and automated experimental workflows for biological research.>CN¥100MPre-A · Nov 16, 2026